Scompenso cardiaco e impatto economico: un’analisi nella reale pratica clinica in Italia.

Content Provider	Europe PMC
Author	Dovizio, Melania Leogrande, Melania Esposti, Luca Degli
Copyright Year	2024
Description	Heart failure and economic impact: an analysis in real clinical practice in ItalyIntroduction:Heart failure (HF) affects 1% of subjects aged 45-55 and over 10% of subjects aged ≥ 80 and in Italy represents the third leading cause of hospitalization.Objective:To analyse the clinical and economic burden of HF in the Italian real clinical practice.Methods:A retrospective analysis was conducted on the administrative databases of healthcare institutions for 4.2 million health-assisted residents. Between January 2012 and March 2021, patients with a hospital discharge diagnosis for HF were included. Among healthcare utilization and costs, treatments, hospitalizations, and specialist services were evaluated. The HF group was compared with a population without HF (no-HF) similar for age, sex distribution, and cardiovascular risk factors.Results:The same number of patients with (N = 74,085) and without HF (N = 74,085) was included. A profile of cardiovascular comorbidities emerged in the HF group, mainly hypertension (88.6%), cardiovascular disease (61.3%) and diabetes (32.1%). Hospitalizations from any cause were 635.6 vs 429.8/1,000 person-year in the HF vs no-HF group. At one-year follow-up, all-cause mortality was 24.9% in HF patients and 8.4% in no-HF. Resource utilization/patient was respectively 26.8 ± 15.9 vs 17.1 ± 12.5 for medications, 0.8 ± 1.2 vs 0.3 ± 0.8 for hospitalizations, and 9.4 ± 12.6 vs 6.5 ± 9.8 for specialist services. This resource utilization resulted in significantly higher total healthcare costs in the HF group vs no-HF group (€ 5,910 vs € 3,574, p < 0.001), mainly related to hospitalizations (€ 3,702 vs € 1,958).Conclusions:HF patients show a significantly higher clinical and economic burden than no-HF, with total healthcare costs being about 1.7 times the costs of the no-HF group.
Abstract	Heart failure and economic impact: an analysis in real clinical practice inItalyIntroduction:Heart failure (HF) affects 1% of subjects aged 45-55 and over 10% of subjectsaged ≥ 80 and in Italy represents the third leading cause ofhospitalization.Objective:To analyse the clinical and economic burden of HF in the Italian realclinical practice.Methods:A retrospective analysis was conducted on the administrative databases ofhealthcare institutions for 4.2 million health-assisted residents. BetweenJanuary 2012 and March 2021, patients with a hospital discharge diagnosisfor HF were included. Among healthcare utilization and costs, treatments,hospitalizations, and specialist services were evaluated. The HF group wascompared with a population without HF (no-HF) similar for age, sexdistribution, and cardiovascular risk factors.Results:The same number of patients with (N = 74,085) and without HF (N = 74,085) wasincluded. A profile of cardiovascular comorbidities emerged in the HF group,mainly hypertension (88.6%), cardiovascular disease (61.3%) and diabetes(32.1%). Hospitalizations from any cause were 635.6 vs 429.8/1,000person-year in the HF vs no-HF group. At one-year follow-up, all-causemortality was 24.9% in HF patients and 8.4% in no-HF. Resourceutilization/patient was respectively 26.8 ± 15.9 vs 17.1 ± 12.5for medications, 0.8 ± 1.2 vs 0.3 ± 0.8 for hospitalizations, and9.4 ± 12.6 vs 6.5 ± 9.8 for specialist services. This resourceutilization resulted in significantly higher total healthcare costs in theHF group vs no-HF group (€ 5,910 vs € 3,574, p < 0.001),mainly related to hospitalizations (€ 3,702 vs € 1,958).Conclusions:HF patients show a significantly higher clinical and economic burden thanno-HF, with total healthcare costs being about 1.7 times the costs of theno-HF group.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC11060510&blobtype=pdf
ISSN	22842403
Volume Number	11
DOI	10.33393/grhta.2024.3013
PubMed Central reference number	PMC11060510
PubMed reference number	38690121
Journal	Global & Regional Health Technology Assessment [Glob Reg Health Technol Assess]
e-ISSN	22835733
Language	English
Publisher	AboutScience
Publisher Date	2024-01-01
Access Restriction	Open
Rights License	Global & Regional Health Technology Assessment - www.aboutscience.eu/grhta © 2024 The Authors.
Subject Keyword	Cardiovascular comorbidities Healthcare costs Heart failure Hospitalizations
Content Type	Text
Resource Type	Article
Subject	Medicine